Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial

BACKGROUND: Fosgonimeton (ATH-1017) is being developed as a first-in-class regenerative therapy for people with Alzheimer’s disease (AD) and dementia; potentially improving dementia symptoms and altering disease progression by reversing synaptic disconnection and neuronal loss. OBJECTIVE: This rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Xue, Church, Kevin, Walker, William, L’Hostis, Philippe, Viardot, Geoffrey, Danjou, Philippe, Hendrix, Suzanne, Moebius, Hans J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108585/
https://www.ncbi.nlm.nih.gov/pubmed/35180125
http://dx.doi.org/10.3233/JAD-215511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108585/
https://www.ncbi.nlm.nih.gov/pubmed/35180125
http://dx.doi.org/10.3233/JAD-215511

Ejemplares similares